Now showing items 1-1 of 1

    • Soluble Receptor for Advanced Glycation End-products (sRAGE) and colorectal cancer risk: a 1 case-control study nested within a European prospective cohort 

      Aglago, Elom K.; Rinaldi, Sabina; Freisling, Heinz; Jiao, Li; Hughes, David J.; Fedirko, Veronika; Schalkwijk, Casper C; Weiderpass, Elisabete; Dahm, Christina C.; Overvad, Kim; Eriksen, Anne Kirstine; Kyrø, Cecilie; Boutron-Ruault, Marie-Christine; Rothwell, Joseph A.; Severi, Gianluca; Katzke, Verena; Kuhn, Tilman; Schulze, Matthias B.; Krasimira, Aleksandrova; Masala, Giovanna; Krogh, Vittorio; Panico, Salavatore; Tumino, Rosario; Naccarati, Alessio; Bueno-De-Mesquita, Bas; van Gils, Carla H.; Sandanger, Torkjel M; Gram, Inger Torhild; Skeie, Guri; Quiros, J. Ramon; Jakszyn, Rachel; Sanchez, Maria-Jose; Amiano, Pilar; Huerta, Jose Maria; Ardanaz, Eva; Johansson, Ingegerd; Harlid, Sophia; Perez-Cornago, Aurora; Mayén, Ana-Lucia; Cordova, Reynalda; Gunter, Marc J.; Vineis, Paolo; Cross, Amanda J.; Riboli, Elio; Jenab, Mazda (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-10-20)
      <p>Background: Overexpression of the receptor for advanced glycation end-product (RAGE) has been associated with chronic inflammation, which in turn has been associated with increased colorectal cancer risk. Soluble RAGE (sRAGE) competes with RAGE to bind its ligands, thus potentially preventing RAGE-induced inflammation. <p>Methods: To investigate whether sRAGE and related genetic variants are ...